A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Clinical trial NCT02990416 · UNKNOWN
Trial details
- NCT number
- NCT02990416
- Sponsor
- Virogen Biotechnology Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-01
- Primary completion
- 2018-02-01
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.